612 Antimalarials

Toxoplasmosis. Pyrimethamine is given, usually with sulfadiazine or another appropriate sulphonamide, in the treatment of toxoplasmosis (p.826). Folinic acid is also given to counteract the megaloblastic anaemia associated with these drugs.

Oral doses suggested by WHO1 are:

- in pregnancy (second and third trimesters), pyrimethamine 25 mg daily for 3 to 4 weeks with sulfadiazine 3 g daily in 4 divided doses
- · in neonates, pyrimethamine 1 mg/kg daily, with sulfadiazine 85 mg/kg daily in 2 divided doses; treatment should be given for 6 months if there is overt neonatal disease, or for 4 weeks to those without overt disease but whose mother was infected during pregnancy
- in immunodeficiency, pyrimethamine 200 mg in divided doses on the first day, then 75 to 100 mg daily for at least 6 weeks, followed by a suppressive dose of 25 to 50 mg daily; sulfadiazine is also given in a dose of 4 to 6 g daily in 4 divided doses for at least 6 weeks, followed by a suppressive dose of 2 to 4 g daily
- in chorioretinitis, pyrimethamine 75 mg daily for 3 days, then 25 mg daily for 4 weeks, followed in unresponsive patients by 50 mg daily for a further 4 weeks; sulfadiazine is also given in a dose of 2 g daily in 4 divided doses

Pyrimethamine with clindamycin is an alternative in patients unable to tolerate a sulfonamide.

Other drugs that have been tried with pyrimethamine include azithromycin,2 clarithromycin,3 and doxycycline.4

Alternative regimens tried for long-term maintenance therapy in patients with AIDS have included pyrimethamine plus sulfadi-azine given twice weekly^{6,7} or pyrimethamine alone in doses of 25 mg or 50 mg daily or 50 mg three times weekly.⁸⁻¹⁰ However, results from a study involving 396 patients suggested that the mortality rate was higher in those receiving pyrimethamine 25 mg three times weekly for primary prophylaxis than in those receiving placebo.¹¹ Pyrimethamine with dapsone given once a week can provide effective prophylaxis but was not well tolerated.12 Pyrimethamine with sulfadoxine, also given once weekly, was of benefit in bone-marrow transplant recipients.15

1. WHO. WHO model formulary. Geneva: WHO, 2004.

- Saba J, et al. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis 1993; 12: 853–6.
- Fernandez-Martin J, et al. Pyrimethamine-clarithromycin com-bination therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother 1991; 35: 2049–52.
- 4. Morris JT, Kelly JW. Effective treatment of cerebral toxoplasmosis with doxycycline. Am J Med 1992; 93: 107-8.
- Hagberg L, et al. Doxycycline and pyrimethamine for toxoplas-mic encephalitis. Scand J Infect Dis 1993; 25: 157–60.
- 6. Pedrol E, et al. Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS 1990; 4: 511-17.
- Podzanczer D, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1995; 123: 175–80.
- Murphy K, et al. Pyrimethamine alone as long-term suppressiv therapy in cerebral toxoplasmosis. Am J Med 1994; 96: 95–6.
- 9. de Gans J, et al. Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1992; 5: 137-42.
- Leport C, et al. Pyrimethamine for primary prophylaxis of tox-oplasmic encephalitis in patients with human immunodeficien-cy virus infection: a double-blind, randomized trial. J Infect Dis 1996; **173:** 91–7.
- Jacobson MA. et al. Primary prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced human immunodeficiency virus disease: results of a randomized trial. J Infect Dis 1994; 169: 384–94.
- 12. Opravil M, et al. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophy-laxis for Pneumocystis carini pneumonia and toxoplasmic en-cephaltisi n human immunodeficiency virus-infected patients. *Clin Infect Dis* 1995; **20**: 531–41.
- Foot ABM, et al. Prophylaxis of toxoplasmosis infection with pyrimethamine/sulfadoxine (Fansidar) in bone marrow trans-plant recipients. Bone Marrow Transplant 1994; 14: 241–5.

Preparations

BP 2008: Pyrimethamine Tablets; USP 31: Pyrimethamine Tablets; Sulfadoxine and Pyrimethamine Tablets.

Proprietary Preparations (details are given in Part 3) Arg.: Darapriny, Austrol.: Daraprim, Austria: Daraprim, Belg.: Daraprim, Broz.: Daraprin, Canad.: Daraprim, Chile: Daraprim, Fr.: Malocide: Ger.: Daraprim, Irl.: Daraprim†, Israel: Daraprim†, Maloyia: Fansidar; Mex.: Daraprim, Neth.: Daraprim, Pol.: Daraprim, S.Afr.: Daraprim; Spain: Daraprim, **Switz.** Daraprim, **Foi.** Daraprim; **S.Afr.** Daraprim; **Switz.** Daraprim; **Thai.** Daraprim; **UK:** Daraprim; **USA:** Daraprim; **UK:** D


Multi-ingredient: Austrol.: Fansidar; Maloprim; Belg.: Co-Arinate; Daf-rafin; Malastop†; Broz.: Fansidar; Canad.: Fansidar†; Denm.: Fansidar; Fr.: Fansidar; India: Artemal†; Laridox; Pyralfin; Pyramet; Rimodar; Indon.: Fansidar; Sudox; Id.: Fansidar; Maloprim†; Israel: Fansidar; Rul.: Metakelf-in; Malaysia: Madomine; Philipp.: Fansidar; S.Afr.: Fansidar; Maloprim†; Singapore: Madomine†; Pyrisone; Switz: Fansidar; Fansidar; Thal.: Vivaxine†; UK: Fansidar; USA: Fansidar.

Pyronaridine Phosphate (HNNM)

Fosfato de pironaridina; Malaridine Phosphate; Pyronaridine, Phosphate de; Pyronaridini Phosphas. 7-Chloro-2-methoxy-10-[3,5-bis(pyrrolidinomethyl)-4-hydroxyanilino]benzo-[b]-1,5naphthyridine phosphate.

Пиронаридина Фосфат

C₂₉H₃₂CIN₅O₂,4H₃PO₄ = 910.0. CAS — 74847-35-1 (pyronaridine); 76748-86-2 (pyronaridine phosphate).



(pyronaridine)

Pharmacopoeias. In Chin.

Profile

Pyronaridine is a naphthyridine derivative used in China in the treatment of vivax malaria and chloroquine-resistant falciparum malaria. Its use has also been investigated in Africa and in Thailand. Combination of pyronaridine with artesunate is also being investigated. Pyronaridine has been given as the phosphate by mouth or by intramuscular or intravenous injection.

◊ References.


- 1. Shao B-R. A review of antimalarial drug pyronaridine. Chin Med 1 1990 · 103 · 428-34
- 2. Shao B-R, et al. A 5-year surveillance of sensitivity in vivo of Plasmodium falciparum to pyronaridine/sulfadoxine/pyrimeth-amine in Diaoluo area, Hainan province. *Southeast Asian J Trop Med Public Health* 1991; 22: 65–7.
- 3. Chen C, et al. Studies on a new antimalarial compound: pyronaridine. Trans R Soc Trop Med Hyg 1992; 86: 7-10.
- 4. Winstanley P. Pyronardine: a promising drug for Africa? Lancet 1996; 347: 2–3. 5. Ringwald P, et al. Randomised trial of pyronaridine versus chlo-
- roquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996; 347: 24-8.
- 6. Looareesuwan S, et al. Pyronaridine. Lancet 1996; 347: 1189-90.
- 7. Anonymous. Pyronaridine: yet another promising antimalarial substance from China. *WHO Drug Inf* 1996; **10:** 9–10.
- Looareesuwan S, et al. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thai-land. Am J Trop Med Hyg 1996; 54: 205–9.
- Ringwald P, et al. Efficacy of oral pyronaridine for the treatment of acute uncomplicated falciparum malaria in African children. Clin Infect Dis 1998; 26: 946-53.

Quinine (BAN)

Chinina; Chininum; Kiniini; Kinin; Quinina. (85,9R)-6'-Methoxycinchonan-9-ol; (αR)-α-(6-Methoxy-4-quinolyl)-α-[(25,45,5R)-(5-vinylquinuclidin-2-yl)]methanol. $C_{20}H_{24}N_2O_2 = 324.4.$

CAS — 130-95-0 (anhydrous quinine).

ATC - POIBCOI.



Description. Quinine is the chief alkaloid of various species of Cinchona (Rubiaceae). It is an optical isomer of quinidine

Quinine Bisulfate

Chininum Bisulfuricum; Neutral Quinine Sulphate; Quinina, bisulfato de; Quinine Acid Sulphate; Quinine Bisulphate (BANM); Ouinini Bisulfas

 $C_{20}H_{24}N_2O_2,H_2SO_4,7H_2O = 548.6.$ CAS — 549-56-4 (anhydrous quinine bisulfate). ATC - POIBCOI.

Pharmacopoeias. In Br., Int., and Viet.

BP 2008 (Quinine Bisulphate). Colourless crystals or a white crystalline powder. It effloresces in dry air. Freely soluble in water; sparingly soluble in alcohol. A 1% solution in water has a pH of 2.8 to 3.4. Protect from light.

Quinine Dihydrochloride (BANM)

Chinini Dihydrochloridum: Neutral Ouinine Hydrochloride: Quinina, dihidrocloruro de; Quinine Acid Hydrochloride; Quinini Dihydrochloridum

 $C_{20}H_{24}N_2O_2,2HCI = 397.3.$ CAS - 60-93-5. ATC - P0IBCOI.

Pharmacopoeias. In Br., Chin., and Int.

Viet. includes the injection. BP 2008 (Quinine Dihydrochloride). A white or almost white powder. Very soluble in water; soluble in alcohol. A 3% solution in water has a pH of 2.0 to 3.0. Protect from light.

Quinine Etabonate

Euquinina; Euquinine; Quinina, etilcarbonato de; Quinine Ethyl Carbonate.

 $C_{23}H_{28}N_2O_4 = 396.5$ CAS — 83-75-0. ATC - POIBCOI

Pharmacopoeias. In Jpn.

Quinine Hydrobromide (BANM)

Basic Quinine Hydrobromide; Chinini Bromidum; Quinina, hidrobromuro de; Quinine Monohydrobromide.

C₂₀H₂₄N₂O₂,HBr,H₂O = 423.3. CAS — 549-49-5 (anhydrous quinine hydrobromide). ATC — P01BC01.

Pharmacopoeias. In Fr.

Quinine Hydrochloride (BANM)

Basic Quinine Hydrochloride; Chinin hydrochlorid dihydrát; Chinini hydrochloridum; Chininii Chloridum; Chininium Chloratum; Chinino hidrochloridas; Chininum Hydrochloricum; Chininy chlorowodorek; Kiniinihydrokloridi; Kinin-hidroklorid; Kininhydroklorid; Quinina, hidrocloruro de; Quinine, chlorhydrate de; Quinine Monohydrochloride; Quinini Hydrochloridum; Quinini Hydrochloridum Dihydricum.

Pharmacopoeias. In Eur. (see p.vii), Int., Jpn, and Viet.

Ph. Eur. 6.2 (Quinine Hydrochloride). White or almost white, or colourless, fine, silky needles, often grouped in clusters. Soluble in water; freely soluble in alcohol. A 1% solution in water has a pH of 6.0 to 6.8. Protect from light.

Quinine Sulfate

Basic Quinine Sulphate; Chinin sulfát dihydrát; Chinini sulfas; Chinino sulfatas; Chininum Sulfuricum; Chininy siarczan; Kiniinisulfaatti; Kininsulfat; Kinin-szulfát; Quinina, sulfato de; Quinine, sulfate de; Quinine Sulphate (BANM); Quinini Sulfas; Quinini Sulfas Dihydricus.

(C₂H₂₄N₂O₂)₂,H₂SO₄,2H₂O = 782.9. CAS — 804-63-7 (anhydrous quinine sulfate); 6119-70-6 (quinine sulfate dihydrate). ATC — P01BC01.

Pharmacopoeias. In Chin., Eur. (see p.vii), Int., Jpn, US, and

Ph. Eur. 6.2 (Quinine Sulphate). A white or almost white, crystalline powder or fine, colourless needles. Slightly soluble in water; sparingly soluble in boiling water and in alcohol. A 1% sus-

pension in water has a pH of 5.7 to 6.6. Protect from light. **USP 31** (Quinine Sulfate). It is the sulfate of an alkaloid obtained from the bark of species of Cinchona. White, odourless, fine needle-like crystals, usually lusterless, making a light and readily compressible mass. It darkens on exposure to light. Soluble 1 in 500 of water and 1 in 120 of alcohol; sparingly soluble in water at 100°; slightly soluble in chloroform; freely soluble in alcohol at 80° and in a mixture of 2 parts of chloroform and one part of dehydrated alcohol; very slightly soluble in ether; Its saturated solution in water is neutral or alkaline to litmus. Protect from light.

Sorption. For reference to loss of quinine sulfate from solutions during membrane filtration, see Chloroquine, p.599.

Adverse Effects

Quinine or its salts given in usual therapeutic doses may give rise to a train of symptoms known as cinchonism, characterised in its mild form by tinnitus, impaired hearing, headache, nausea, and disturbed vision, with, in its more severe manifestations, vomiting, abdominal pain, diarrhoea, and vertigo.